Healthcare Services company Metropolis Healthcare announced Q3FY25 results Revenue: Rs 323 crore compared to Rs 291 crore during Q3FY24, change 10.9%. EBITDA: Rs 72 crore compared to Rs 66 crore during Q3FY24, change 9.4%. EBITDA margin: 22.20% for Q3FY25. PAT: Rs 31 crore compared to Rs 27 crore during Q3FY24, change 15.3%. PAT margin: 9.8% for Q3FY25. Ameera Shah, Executive Chairperson & Whole-time Director, Metropolis Healthcare, said: “The diagnostics industry is undergoing a paradigm shift towards personalized medicine, genomics-driven testing, and preventive healthcare, fueled by advancements in molecular diagnostics, AI, and nextgeneration sequencing. At Metropolis, we remain at the forefront of this transformation, leveraging deep scientific expertise and consumer insights to drive innovation and expand access to cutting-edge diagnostics. Our strategic acquisition of Core Diagnostics is a pivotal step in this direction, strengthening our oncology and molecular diagnostics portfolio and reinforcing our commitment to becoming India’s leading cancer testing provider. As part of our long-term strategy, we are expanding our presence in North India through a ‘string of pearls’ approach, focusing on acquiring high-performing B2C businesses that are leaders in their cities, with strong EBITDA, ROCE, and cash flows. This strategy will enhance our capabilities and deepen our footprint in the region, driving long-term value creation and solidifying Metropolis’ leadership in the evolving diagnostics landscape." Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare, said: “We have achieved double-digit growth for the third consecutive quarter, despite a traditionally challenging Q3 with lower illness-driven demand. This success stems from our focus on key segments, TruHealth and Specialty, and our efforts to drive regional growth through targeted micro-marketing strategies and deeper market penetration. Through TruHealth™ packages, we have been able to enhance the customer experience by integrating home-based ECG services, vital checks, and consultations. Additionally, the introduction of AI-powered MetAdvisor recommendation engine further personalises care by analysing historical data and test combinations. With strong partnerships and an expanding network, we remain committed to addressing regional healthcare needs and driving sustainable growth. Our continued investments in technology and service excellence will deliver lasting value to customers and stakeholders. Result PDF
Conference Call with Metropolis Healthcare Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.